Tvardi Therapeutics (TVRD) EBT (2013 - 2026)
Tvardi Therapeutics (TVRD) posted EBT of -$7.6 million for Q1 2026, up 13.12% sequentially from -$8.7 million in Q4 2025, and up 21.16% YoY from -$6.2 million in Q1 2025.
Tvardi Therapeutics (TVRD) EBT (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported EBT for 14 years, with the latest figure at -$7.6 million in Q1 2026.
- Quarterly EBT rose 21.16% year-over-year to -$7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$82.2 million (down 120.46% YoY) and the FY2025 annual result came in at -$27.8 million, up 60.95% from the prior year.
- EBT advanced to -$7.6 million in Q1 2026 per TVRD's latest filing, from -$8.7 million in the prior quarter.
- Over five years, EBT peaked at -$7.1 million in Q2 2024 and troughed at -$40.0 million in Q3 2025.
- A 5-year average of -$21.9 million and a median of -$26.3 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2024: EBT slumped 2499.31% in 2022, then soared 78.39% in 2024.
- Over 5 years, EBT stood at -$31.8 million in 2022, then decreased by 4.12% to -$33.1 million in 2023, then soared by 67.63% to -$10.7 million in 2024, then increased by 18.91% to -$8.7 million in 2025, then climbed by 13.12% to -$7.6 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$7.6 million, -$8.7 million, and -$40.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 81.49 Mn |
| 10 | Tvardi Therapeutics | 17.59 Mn | 17.59 Mn | - | -6.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.55 Mn |
| Dec 31, 2025 | -8.69 Mn |
| Sep 30, 2025 | -40.00 Mn |
| Jun 30, 2025 | -25.92 Mn |
| Mar 31, 2025 | -9.58 Mn |
| Dec 31, 2024 | -10.72 Mn |
| Sep 30, 2024 | -9.88 Mn |
| Jun 30, 2024 | -7.10 Mn |
| Mar 31, 2024 | -31.03 Mn |
| Dec 31, 2023 | -33.11 Mn |
| Sep 30, 2023 | -30.30 Mn |
| Jun 30, 2023 | -32.84 Mn |
| Mar 31, 2023 | -29.15 Mn |
| Dec 31, 2022 | -31.80 Mn |
| Sep 30, 2022 | -26.33 Mn |
| Jun 30, 2022 | -7.45 Mn |
| Mar 31, 2022 | -31.38 Mn |
| Dec 31, 2021 | -33.38 Mn |
| Sep 30, 2021 | -1.01 Mn |
| Jun 30, 2021 | -30.75 Mn |